Turtle Creek Wealth Advisors LLC Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

Turtle Creek Wealth Advisors LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 43,787 shares of the company's stock, valued at approximately $3,218,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Bleakley Financial Group LLC grew its stake in shares of AstraZeneca by 14.8% in the 1st quarter. Bleakley Financial Group LLC now owns 69,761 shares of the company's stock valued at $5,127,000 after purchasing an additional 8,986 shares during the last quarter. MQS Management LLC purchased a new position in AstraZeneca in the 1st quarter valued at $422,000. Oxbow Advisors LLC increased its stake in AstraZeneca by 2.0% in the 1st quarter. Oxbow Advisors LLC now owns 38,108 shares of the company's stock valued at $2,801,000 after buying an additional 765 shares during the period. New York State Common Retirement Fund raised its position in AstraZeneca by 1.7% during the 1st quarter. New York State Common Retirement Fund now owns 135,357 shares of the company's stock worth $9,949,000 after buying an additional 2,314 shares during the last quarter. Finally, Kathmere Capital Management LLC lifted its stake in shares of AstraZeneca by 83.7% in the 1st quarter. Kathmere Capital Management LLC now owns 9,290 shares of the company's stock worth $683,000 after acquiring an additional 4,232 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AZN shares. BNP Paribas began coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and an average price target of $89.00.

AstraZeneca Price Performance

AZN stock traded up $0.61 during trading on Monday, reaching $71.74. 3,401,722 shares of the company were exchanged, compared to its average volume of 5,335,998. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The stock's 50 day moving average price is $70.72 and its 200 day moving average price is $70.84. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a market cap of $222.49 billion, a P/E ratio of 28.81, a PEG ratio of 1.31 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same quarter in the previous year, the company earned $2.06 EPS. The company's quarterly revenue was up 7.2% on a year-over-year basis. As a group, analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.